Targets › HRH1
29 programs from 27 companies in 34 trials: 18 Phase 2, 7 Phase 3, 6 Phase 1, 3 Phase 4; Immunology, Other, Neurology; next expected readout Nov 2026.
G protein-coupled receptor for histamine, a biogenic amine that functions as an immune modulator and a neurotransmitter. Through the H1 receptor, histamine mediates the contraction of smooth muscles and increases capillary permeability due to contraction of terminal venules. (UniProt, P35367)
Open in Phaseline: the race on HRH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kasr El Aini Hospital | chlorpheniramine Histamine H1 receptor antagonist | HRH1 | Phase 4 | Blood Transfusion Associated Adverse Reactions | Nov 2026 |
| University of Rochester | Diphenhydramine Histamine H1 receptor antagonist | HRH1 | Phase 4 | Pain | Feb 2027 |
| University of Pennsylvania | Diphenhydramine Histamine H1 receptor antagonist | HRH1 | Phase 4 | Insomnia | Jan 2032 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Fexofenadine Histamine H1 receptor antagonist | HRH1 | Phase 3 | Zhejiang University; ST-segment Elevation Myocardial Infarction (STEMI) | Dec 2026 |
| Craig A. Friesen, MD | Ketotifen H1 receptor antagonist and mast cell stabilizer | HRH1 | Phase 3 | Functional Dyspepsia | Apr 2027 |
| Florida Atlantic University | Diphenhydramine Histamine H1 receptor antagonist | HRH1 | Phase 3 | Laceration of Skin | Jun 2027 |
| Guy Boeckxstaens | Ebastine Histamine 1 receptor antagonist | HRH1 | Phase 3 | IBS - Irritable Bowel Syndrome | Oct 2027 |
| Shandong New Time Pharmaceutical | Cetirizine Histamine H1 receptor antagonist | HRH1 | Phase 3 | Acute Urticaria | – |
| Tanta University | Ketotifen Oral Tablet H1 receptor antagonist (antihistamine) | HRH1 | Phase 3 | Neuropathy;Peripheral | – |
| Horus University | Desloratadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Rheumatoid Arthritis (RA); Rheumatoid Arthritis | Nov 2026 |
| AHS Cancer Control Alberta | Loratadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Stem Cell Transplant Complications | Dec 2026 |
| Tanta University | Fexofenadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Parkinson Disease | Dec 2026 |
| University of Illinois Chicago | Clemastine Fumarate Histamine H1 receptor antagonist | HRH1 | Phase 2 | Depression | Dec 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | Chlorpheniramine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Allergic Transfusion Reaction | Dec 2026 |
| Tanta University | desloratadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Ulcerative Colitis (UC) | Feb 2027 |
| The University of Texas Health Science Center, Houston | Diphenhydramine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Labor Dystocia | Mar 2027 |
| University of California, San Francisco | Clemastine fumarate Histamine H1 receptor antagonist | HRH1 | Phase 2 | Optic Neuritis; Multiple Sclerosis (MS) | Jun 2027 |
| Val Adams | Loratadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Solid Tumors | Jul 2027 |
| Laval University | Cyproheptadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Ischemic Mitral Regurgitation | Sep 2027 |
| Chuan Qin | Terfenadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Relapsing Remitting Multiple Sclerosis | Oct 2027 |
| Stanford University | Diphenhydramine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Autism | Dec 2027 |
| Montefiore Medical Center | Desloratadine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Breast Cancer | Dec 2029 |
| Sheba Medical Center | Clemastine Histamine H1 receptor antagonist | HRH1 | Phase 2 | Williams Syndrome | – |
| Md. Hazrat Ali | ebastine H1 receptor antagonist (antihistamine) | HRH1 | Phase 2 | Irritable Bowel Syndrome - Diarrhoea | – |
| Bridget LaMonica Ostrem, M.D., Ph.D. | Clemastine fumarate Histamine H1 receptor antagonist | HRH1 | Phase 1 | White Matter Injury | Apr 2028 |
| University of Colorado, Denver | Clemastine Fumarate Histamine H1 receptor antagonist | HRH1 | Phase 1 | Central Auditory Processing Disorder | Jul 2028 |
| D. Walter Wray | Fexofenadine Histamine H1 receptor antagonist | HRH1 | Phase 1 | Chronic Obstructive Pulmonary Disease | Aug 2030 |
| October 6 University | Fexofenadine Histamine H1 receptor antagonist | HRH1 | Phase 1 | Rheumatoid Arthritis | – |
| Noucor Health | Rupatadine Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist | PTAFR, HRH1 | Phase 1 | Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis | – |
Rheumatoid Arthritis (3) IBS - Irritable Bowel Syndrome (1) Central Auditory Processing Disorder (1) Labor Dystocia (1) Insomnia (1) Acute Urticaria (1) Chronic Obstructive Pulmonary Disease (1) Parkinson Disease (1) Solid Tumors (1) Ulcerative Colitis (UC) (1) Ischemic Mitral Regurgitation (1) Depression (1)
small molecule (28), mixed (1)
Tanta University (3) Guy Boeckxstaens (1) October 6 University (1) University of Colorado, Denver (1) The University of Texas Health Science Center, Houston (1) University of Pennsylvania (1) Shandong New Time Pharmaceutical (1) D. Walter Wray (1) Val Adams (1) Laval University (1) University of Illinois Chicago (1) Institute of Hematology & Blood Diseases Hospital, China (1) Stanford University (1) Bridget LaMonica Ostrem, M.D., Ph.D. (1) Md. Hazrat Ali (1) Kasr El Aini Hospital (1) AHS Cancer Control Alberta (1) Noucor Health (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) University of California, San Francisco (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.